Navigation Links
Better Treatment Found for Crohn's Disease
Date:4/14/2010

Two drugs aimed at taming overactive immune system worked best, study found

WEDNESDAY, April 14 (HealthDay News) -- Combination therapy with two drugs that control an unruly immune system provided the best relief yet seen for Crohn's disease, a condition in which the body mistakenly attacks its own intestinal tissue.

The new finding promises to change current treatment of Crohn's disease, said study leader Dr. William J. Sandborn, vice chair of gastroenterology and hepatology at the Mayo Clinic in Rochester, Minn.

The results were reported in the April 15 issue of the New England Journal of Medicine.

Doctors now start treatment of Crohn's disease with steroids, Sandborn said. If the steroids do not provide relief from the abdominal pain, nausea, fever, weight loss, diarrhea and other symptoms of the condition, the next step is to use azathioprine, which reduces immune system activity broadly. Only if that fails will they try biologics, newer treatments that include monoclonal antibodies such as infliximab (Remicade). These drugs target a specific part of the immune system.

The trial showed that the azathioprine-alone step should be skipped. "This study suggests that the therapy that follows steroids should include a biologic," Sandborn added.

Therapy with both azathioprine and infliximab appears to be the treatment of choice if steroids are not effective, Sandborn said.

"What this trial shows is that the most effective strategy is combination therapy," he said.

The results will alter treatment of Crohn's disease to some extent, said Dr. Jeffrey A. Katz, a spokesman for the Crohn's and Colitis Foundation of America, but by and large "it really does confirm what other studies suggest and what is clinically apparent, that combination therapy is better than treatment with azathioprine alone."

"It will push me in the direction of using combination therapy a bit more than I have been," said Katz, an associate professor of medicine at Case Western University School of Medicine in Cleveland.

The international trial included 508 people with Crohn's disease who had never been treated with immunosuppressive drugs. One-third were given infliximab alone, one-third received only azathioprine and one-third were treated with both. The trial was funded by Centocor Ortho Biotech, which markets infliximab, and Schering-Plough.

After 26 weeks, 56.8 percent of those getting combination therapy had complete remission of symptoms, compared to 44.4 percent of those getting only infliximab and 30 percent of those getting only azathioprine.

The most worrisome problem with drugs that repress immune system activity is a severe infection. That problem occurred in 3.9 percent of the people who used combination therapy, 4.9 percent of those in the infliximab group and 5.6 percent of those in the azathioprine group, a difference that is not statistically significant, Sandborn said.

And because the combination therapy is more effective, it helps prevent infections that result from ulceration of the intestinal wall caused by Crohn's disease, he added.

Fear of side effects such as serious infections has held back use of the combination therapy, Katz said.

And while the study "answers our questions in a select group of patients," it does not fully resolve the safety issue, said Dr. Simon Lichtiger, an associate professor of gastroenterology at Mount Sinai Medical Center in New York City.

"The safety data aren't fully known and won't be known for a year," Lichtiger said. "It's not clear yet whether the advantages of the therapy exceed the possibility of long-term toxicity."

Crohn's disease is one of the two major forms of inflammatory bowel disease, whose underlying cause remains unclear. The other form is ulcerative colitis. An estimated 1 million Americans suffer from inflammatory bowel disease.

A similar study is underway in people with ulcerative colitis, Sandborn said. Results will not be available "for as much as a year or two," he noted.

More information

Crohn's disease and its treatment are described by the Crohn's and Colitis Foundation of America.



SOURCES: William J. Sandborn M.D., chair, gastroenterology and hepatology, Mayo Clinic, Rochester, Minn.; Jeffrey A. Katz, M.D., spokesman, Crohn's and Colitis Foundation of America; Simon Lichtiger, M.D., associate professor, gastroenterology, Mount Sinai Medical Center, New York City; April 15, 2010, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Flu Vaccine With Both B Strains May Offer Better Protection
2. M. D. Anderson zeroes in on better way to predict prognosis in pediatric leukemia patients
3. Want better health information technology? Ask patients how they want it
4. Building a better flu vaccine: Add second strain of influenza B
5. Maintaining regular daily routines is associated with better sleep quality in older adults
6. Simple Forms Help Docs Do Better Breast Exams
7. My Health and Money Helps Consumers Stretch Their Healthcare Dollars and Make Better Choices
8. Discovery May Lead to Better Multiple Sclerosis Treatments
9. BHR Pharma Statement on Brain Injury Awareness Month - Better Awareness, Treatment, Research Needed Now
10. Pet Insurance Provider Hartville Group Gets A+ Rating From Better Business Bureau
11. The American Heart Association's The Heart of Diabetes Campaign is Helping Patients 'Know Your Diabetes' Better
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare ... Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during ... , The annual award competition recognizes editorial and design excellence across a range of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and ... 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will ... Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... Oct. 11, 2017  BioPharmX Corporation (NYSE MKT: BPMX) ... developed an innovative way to use nonlinear optical imaging ... of new drugs. ... Conference will show how researchers from BioPharmX and the ... School used a suite of imaging techniques in what ...
(Date:10/11/2017)... , Oct. 11, 2017  True Health, a ... amplified its effort during National Breast Cancer Awareness ... cancer risks. ... Oncology calculated that more than 10 million American ... mutations in BRCA1 or BRCA2 and have not had ...
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance ... a medical-grade battery-powered display stand specifically designed for endoscopy environments. An ... technology into a clinical solution to support the improvement of patient ... Innovative Design ... Wireless Solution ...
Breaking Medicine Technology: